Science 4 March 1994: Vol. 263. no. 5151, pp. 1281 - 1284 DOI: 10.1126/science.8122112

Prev | Table of Contents | Next

Articles

Cytoplasmic ACK1 Interaction with Multiple Receptor Tyrosine Kinases Is Mediated by Grb2: AN ANALYSIS OF ACK1 EFFECTS ON Axl SIGNALING.

L. Pao-Chun, P. M. Chan, W. Chan, and E. Manser (2009)
J. Biol. Chem. 284, 34954-34963
 |  Abstract »  |  Full Text »  |  PDF »

Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology.

U. McDermott and J. Settleman (2009)
J. Clin. Oncol. 27, 5650-5659
 |  Abstract »  |  Full Text »  |  PDF »

NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells.

C. Ambrogio, C. Martinengo, C. Voena, F. Tondat, L. Riera, P. F. di Celle, G. Inghirami, and R. Chiarle (2009)
Cancer Res. 69, 8611-8619
 |  Abstract »  |  Full Text »  |  PDF »

Single-Drug Vinblastine As Salvage Treatment for Refractory or Relapsed Anaplastic Large-Cell Lymphoma: A Report From the French Society of Pediatric Oncology.

L. Brugieres, H. Pacquement, M.-C. Le Deley, G. Leverger, P. Lutz, C. Paillard, A. Baruchel, D. Frappaz, B. Nelken, L. Lamant, et al. (2009)
J. Clin. Oncol. 27, 5056-5061
 |  Abstract »  |  Full Text »  |  PDF »

Inhibition of ALK Signaling for Cancer Therapy.

Y. P. Mosse, A. Wood, and J. M. Maris (2009)
Clin. Cancer Res. 15, 5609-5614
 |  Abstract »  |  Full Text »  |  PDF »

The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues.

G. Sozzi, M. P. Martelli, D. Conte, P. Modena, V. Pettirossi, S. A. Pileri, and B. Falini (2009)
Haematologica 94, 1307-1311
 |  Abstract »  |  Full Text »  |  PDF »

Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers.

E. Lin, L. Li, Y. Guan, R. Soriano, C. S. Rivers, S. Mohan, A. Pandita, J. Tang, and Z. Modrusan (2009)
Mol. Cancer Res. 7, 1466-1476
 |  Abstract »  |  Full Text »  |  PDF »

The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways.

M. S. Lim, M. L. Carlson, D. K. Crockett, G. C. Fillmore, D. R. Abbott, O. F. Elenitoba-Johnson, S. R. Tripp, G. Z. Rassidakis, L. J. Medeiros, P. Szankasi, et al. (2009)
Blood 114, 1585-1595
 |  Abstract »  |  Full Text »  |  PDF »

Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population.

S. J. Rodig, M. Mino-Kenudson, S. Dacic, B. Y. Yeap, A. Shaw, J. A. Barletta, H. Stubbs, K. Law, N. Lindeman, E. Mark, et al. (2009)
Clin. Cancer Res. 15, 5216-5223
 |  Abstract »  |  Full Text »  |  PDF »

IL-21 Contributes to JAK3/STAT3 Activation and Promotes Cell Growth in ALK-Positive Anaplastic Large Cell Lymphoma.

J. Dien Bard, P. Gelebart, M. Anand, Z. Zak, S. A. Hegazy, H. M. Amin, and R. Lai (2009)
Am. J. Pathol. 175, 825-834
 |  Abstract »  |  Full Text »  |  PDF »

IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.

P. Shi, R. Lai, Q. Lin, A. S. Iqbal, L. C. Young, L. W. Kwak, R. J. Ford, and H. M. Amin (2009)
Blood 114, 360-370
 |  Abstract »  |  Full Text »  |  PDF »

Analysis of Human T-Cell Lymphotropic Virus in CD25+ Anaplastic Large Cell Lymphoma in Children.

G. Gualco, L. Chioato, L. M. Weiss, W. J. Harrington Jr, and C. E. Bacchi (2009)
Am J Clin Pathol 132, 28-33
 |  Abstract »  |  Full Text »  |  PDF »

Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy.

B. Falini and M. P. Martelli (2009)
Haematologica 94, 897-900
 |  Full Text »  |  PDF »

The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity.

P. Bonvini, E. Zorzi, L. Mussolin, G. Monaco, M. Pigazzi, G. Basso, and A. Rosolen (2009)
Haematologica 94, 944-955
 |  Abstract »  |  Full Text »  |  PDF »

NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner.

Y.-X. Cui, A. Kerby, F. K. E. McDuff, H. Ye, and S. D. Turner (2009)
Blood 113, 5217-5227
 |  Abstract »  |  Full Text »  |  PDF »

KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer.

K. Takeuchi, Y. L. Choi, Y. Togashi, M. Soda, S. Hatano, K. Inamura, S. Takada, T. Ueno, Y. Yamashita, Y. Satoh, et al. (2009)
Clin. Cancer Res. 15, 3143-3149
 |  Abstract »  |  Full Text »  |  PDF »

Therapeutic Implications of ALK Mutations in Neuroblastoma.

R. E. George and A. Thomas Look (2009)
Am. Assoc. Cancer Res. Educ. Book 2009, 113-115
 |  Full Text »  |  PDF »

Unraveling ALK signaling through phosphoproteomics.

M. S. Lim (2009)
Blood 113, 2615-2616
 |  Full Text »  |  PDF »

Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models.

M. G. Cornejo, M. G. Kharas, M. B. Werneck, S. L. Bras, S. A. Moore, B. Ball, M. Beylot-Barry, S. J. Rodig, J. C. Aster, B. H. Lee, et al. (2009)
Blood 113, 2746-2754
 |  Abstract »  |  Full Text »  |  PDF »

Proteome-Wide Identification of Novel Binding Partners to the Oncogenic Fusion Gene Protein, NPM-ALK, using Tandem Affinity Purification and Mass Spectrometry.

F. Wu, P. Wang, L. C. Young, R. Lai, and L. Li (2009)
Am. J. Pathol. 174, 361-370
 |  Abstract »  |  Full Text »  |  PDF »

EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues.

M. P. Martelli, G. Sozzi, L. Hernandez, V. Pettirossi, A. Navarro, D. Conte, P. Gasparini, F. Perrone, P. Modena, U. Pastorino, et al. (2009)
Am. J. Pathol. 174, 661-670
 |  Abstract »  |  Full Text »  |  PDF »

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).

M. Marzec, Q. Zhang, A. Goradia, P. N. Raghunath, X. Liu, M. Paessler, H. Y. Wang, M. Wysocka, M. Cheng, B. A. Ruggeri, et al. (2008)
PNAS 105, 20852-20857
 |  Abstract »  |  Full Text »  |  PDF »

The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation.

C. Ambrogio, C. Voena, A. D. Manazza, C. Martinengo, C. Costa, T. Kirchhausen, E. Hirsch, G. Inghirami, and R. Chiarle (2008)
Cancer Res. 68, 8899-8907
 |  Abstract »  |  Full Text »  |  PDF »

Rapid Method for Detection of Mutations in the Nucleophosmin Gene in Acute Myeloid Leukemia.

T. S. Laughlin, M. W. Becker, J. L. Liesveld, D. A. Mulford, C. N. Abboud, P. Brown, and P. G. Rothberg (2008)
J. Mol. Diagn. 10, 338-345
 |  Abstract »  |  Full Text »  |  PDF »

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer.

J. P. Koivunen, C. Mermel, K. Zejnullahu, C. Murphy, E. Lifshits, A. J. Holmes, H. G. Choi, J. Kim, D. Chiang, R. Thomas, et al. (2008)
Clin. Cancer Res. 14, 4275-4283
 |  Abstract »  |  Full Text »  |  PDF »

Ribosomal Protein S9 Is a Novel B23/NPM-binding Protein Required for Normal Cell Proliferation.

M. S. Lindstrom and Y. Zhang (2008)
J. Biol. Chem. 283, 15568-15576
 |  Abstract »  |  Full Text »  |  PDF »

Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors.

U. McDermott, A. J. Iafrate, N. S. Gray, T. Shioda, M. Classon, S. Maheswaran, W. Zhou, H. G. Choi, S. L. Smith, L. Dowell, et al. (2008)
Cancer Res. 68, 3389-3395
 |  Abstract »  |  Full Text »  |  PDF »

Eight-channel iTRAQ Enables Comparison of the Activity of Six Leukemogenic Tyrosine Kinases.

A. Pierce, R. D. Unwin, C. A. Evans, S. Griffiths, L. Carney, L. Zhang, E. Jaworska, C.-F. Lee, D. Blinco, M. J. Okoniewski, et al. (2008)
Mol. Cell. Proteomics 7, 853-863
 |  Abstract »  |  Full Text »  |  PDF »

Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.

M. H. Tomasson, Z. Xiang, R. Walgren, Y. Zhao, Y. Kasai, T. Miner, R. E. Ries, O. Lubman, D. H. Fremont, M. D. McLellan, et al. (2008)
Blood 111, 4797-4808
 |  Abstract »  |  Full Text »  |  PDF »

Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse.

P. Sportoletti, S. Grisendi, S. M. Majid, K. Cheng, J. G. Clohessy, A. Viale, J. Teruya-Feldstein, and P. P. Pandolfi (2008)
Blood 111, 3859-3862
 |  Abstract »  |  Full Text »  |  PDF »

Characterization of Some Molecular Mechanisms Governing Autoactivation of the Catalytic Domain of the Anaplastic Lymphoma Kinase.

C. J. Tartari, R. H. Gunby, A. M. L. Coluccia, R. Sottocornola, B. Cimbro, L. Scapozza, A. Donella-Deana, L. A. Pinna, and C. Gambacorti-Passerini (2008)
J. Biol. Chem. 283, 3743-3750
 |  Abstract »  |  Full Text »  |  PDF »

Shuttling Imbalance of MLF1 Results in p53 Instability and Increases Susceptibility to Oncogenic Transformation.

N. Yoneda-Kato and J.-y. Kato (2008)
Mol. Cell. Biol. 28, 422-434
 |  Abstract »  |  Full Text »  |  PDF »

Oncogene addiction: setting the stage for molecularly targeted cancer therapy.

S. V. Sharma and J. Settleman (2007)
Genes & Dev. 21, 3214-3231
 |  Abstract »  |  Full Text »  |  PDF »

The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling.

P. B. Staber, P. Vesely, N. Haq, R. G. Ott, K. Funato, I. Bambach, C. Fuchs, S. Schauer, W. Linkesch, A. Hrzenjak, et al. (2007)
Blood 110, 3374-3383
 |  Abstract »  |  Full Text »  |  PDF »

Pathobiology of ALK+ anaplastic large-cell lymphoma.

H. M. Amin and R. Lai (2007)
Blood 110, 2259-2267
 |  Abstract »  |  Full Text »  |  PDF »

NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.

A. Galietta, R. H. Gunby, S. Redaelli, P. Stano, C. Carniti, A. Bachi, P. W. Tucker, C. J. Tartari, C.-J. Huang, E. Colombo, et al. (2007)
Blood 110, 2600-2609
 |  Abstract »  |  Full Text »  |  PDF »

Anaplastic Lymphoma Kinase Is Activated Through the Pleiotrophin/Receptor Protein-tyrosine Phosphatase beta/{zeta} Signaling Pathway: AN ALTERNATIVE MECHANISM OF RECEPTOR TYROSINE KINASE ACTIVATION.

P. Perez-Pinera, W. Zhang, Y. Chang, J. A. Vega, and T. F. Deuel (2007)
J. Biol. Chem. 282, 28683-28690
 |  Abstract »  |  Full Text »  |  PDF »

NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.

V. Leventaki, E. Drakos, L. J. Medeiros, M. S. Lim, K. S. Elenitoba-Johnson, F. X. Claret, and G. Z. Rassidakis (2007)
Blood 110, 1621-1630
 |  Abstract »  |  Full Text »  |  PDF »

The incidence and clinical significance of nucleophosmin mutations in childhood AML.

P. Brown, E. McIntyre, R. Rau, S. Meshinchi, N. Lacayo, G. Dahl, T. A. Alonzo, M. Chang, R. J. Arceci, and D. Small (2007)
Blood 110, 979-985
 |  Abstract »  |  Full Text »  |  PDF »

Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma.

C. Damm-Welk, K. Busch, B. Burkhardt, J. Schieferstein, S. Viehmann, I. Oschlies, W. Klapper, M. Zimmermann, J. Harbott, A. Reiter, et al. (2007)
Blood 110, 670-677
 |  Abstract »  |  Full Text »  |  PDF »

Multisite Phosphorylation of Nuclear Interaction Partner of ALK (NIPA) at G2/M Involves Cyclin B1/Cdk1.

F. Bassermann, C. von Klitzing, A. L. Illert, S. Munch, S. W. Morris, M. Pagano, C. Peschel, and J. Duyster (2007)
J. Biol. Chem. 282, 15965-15972
 |  Abstract »  |  Full Text »  |  PDF »

The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration.

C. Voena, C. Conte, C. Ambrogio, E. Boeri Erba, F. Boccalatte, S. Mohammed, O. N. Jensen, G. Palestro, G. Inghirami, and R. Chiarle (2007)
Cancer Res. 67, 4278-4286
 |  Abstract »  |  Full Text »  |  PDF »

CD30 Activates Both the Canonical and Alternative NF-{kappa}B Pathways in Anaplastic Large Cell Lymphoma Cells.

C. W. Wright, J. M. Rumble, and C. S. Duckett (2007)
J. Biol. Chem. 282, 10252-10262
 |  Abstract »  |  Full Text »  |  PDF »

Evaluation of Enrichment Techniques for Mass Spectrometry: Identification of Tyrosine Phosphoproteins in Cancer Cells.

J. A. Schumacher, D. K. Crockett, K. S.J. Elenitoba-Johnson, and M. S. Lim (2007)
J. Mol. Diagn. 9, 169-177
 |  Abstract »  |  Full Text »  |  PDF »

Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.

B. Falini, I. Nicoletti, N. Bolli, M. P. Martelli, A. Liso, P. Gorello, F. Mandelli, C. Mecucci, and M. F. Martelli (2007)
Haematologica 92, 519-532
 |  Abstract »  |  Full Text »  |  PDF »

Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes.

L. Lamant, A. d. Reynies, M.-M. Duplantier, D. S. Rickman, F. Sabourdy, S. Giuriato, L. Brugieres, P. Gaulard, E. Espinos, and G. Delsol (2007)
Blood 109, 2156-2164
 |  Abstract »  |  Full Text »  |  PDF »

Activation of Peroxisome Proliferator-Activated Receptor {gamma} Contributes to the Survival of T Lymphoma Cells by Affecting Cellular Metabolism.

C. Yang, S.-H. Jo, B. Csernus, E. Hyjek, Y. Liu, A. Chadburn, and Y. L. Wang (2007)
Am. J. Pathol. 170, 722-732
 |  Abstract »  |  Full Text »  |  PDF »

Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.

B. Falini, I. Nicoletti, M. F. Martelli, and C. Mecucci (2007)
Blood 109, 874-885
 |  Abstract »  |  Full Text »  |  PDF »

Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?.

K. Mrozek, G. Marcucci, P. Paschka, S. P. Whitman, and C. D. Bloomfield (2007)
Blood 109, 431-448
 |  Abstract »  |  Full Text »  |  PDF »

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

A. V. Galkin, J. S. Melnick, S. Kim, T. L. Hood, N. Li, L. Li, G. Xia, R. Steensma, G. Chopiuk, J. Jiang, et al. (2007)
PNAS 104, 270-275
 |  Abstract »  |  Full Text »  |  PDF »

Impact of Protein Kinase PKR in Cell Biology: from Antiviral to Antiproliferative Action.

M. A. Garcia, J. Gil, I. Ventoso, S. Guerra, E. Domingo, C. Rivas, and M. Esteban (2006)
Microbiol. Mol. Biol. Rev. 70, 1032-1060
 |  Abstract »  |  Full Text »  |  PDF »

Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells.

L. Qiu, R. Lai, Q. Lin, E. Lau, D. M. Thomazy, D. Calame, R. J. Ford, L. W. Kwak, R. A. Kirken, and H. M. Amin (2006)
Blood 108, 2407-2415
 |  Abstract »  |  Full Text »  |  PDF »

Peroxisome Proliferator-Activated Receptor {gamma} Promotes Lymphocyte Survival through Its Actions on Cellular Metabolic Activities.

S.-H. Jo, C. Yang, Q. Miao, M. Marzec, M. A. Wasik, P. Lu, and Y. L. Wang (2006)
J. Immunol. 177, 3737-3745
 |  Abstract »  |  Full Text »  |  PDF »

NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma.

L. Quintanilla-Martinez, S. Pittaluga, C. Miething, M. Klier, M. Rudelius, T. Davies-Hill, N. Anastasov, A. Martinez, A. Vivero, J. Duyster, et al. (2006)
Blood 108, 2029-2036
 |  Abstract »  |  Full Text »  |  PDF »

Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage..

J. Mourali, A. Benard, F. C. Lourenco, C. Monnet, C. Greenland, C. Moog-Lutz, C. Racaud-Sultan, D. Gonzalez-Dunia, M. Vigny, P. Mehlen, et al. (2006)
Mol. Cell. Biol. 26, 6209-6222
 |  Abstract »  |  Full Text »  |  PDF »

Activation of Mammalian Target of Rapamycin Signaling Pathway Contributes to Tumor Cell Survival in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma..

F. Vega, L. J. Medeiros, V. Leventaki, C. Atwell, J. H. Cho-Vega, L. Tian, F.-X. Claret, and G. Z. Rassidakis (2006)
Cancer Res. 66, 6589-6597
 |  Abstract »  |  Full Text »  |  PDF »

Proteomic identification of oncogenic chromosomal translocation partners encoding chimeric anaplastic lymphoma kinase fusion proteins.

K. S. J. Elenitoba-Johnson, D. K. Crockett, J. A. Schumacher, S. D. Jenson, C. M. Coffin, A. L. Rockwood, and M. S. Lim (2006)
PNAS 103, 7402-7407
 |  Abstract »  |  Full Text »  |  PDF »

Delocalization and Destabilization of the Arf Tumor Suppressor by the Leukemia-Associated NPM Mutant..

E. Colombo, P. Martinelli, R. Zamponi, D. C. Shing, P. Bonetti, L. Luzi, S. Volorio, L. Bernard, G. Pruneri, M. Alcalay, et al. (2006)
Cancer Res. 66, 3044-3050
 |  Abstract »  |  Full Text »  |  PDF »

Nucleophosmin Mutations in De novo Acute Myeloid Leukemia: The Age-Dependent Incidences and the Stability during Disease Evolution..

W.-C. Chou, J.-L. Tang, L.-I. Lin, M. Yao, W. Tsay, C.-Y. Chen, S.-J. Wu, C.-F. Huang, R.-J. Chiou, M.-H. Tseng, et al. (2006)
Cancer Res. 66, 3310-3316
 |  Abstract »  |  Full Text »  |  PDF »

c-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma.

M. P. Oyarzo, L. J. Medeiros, C. Atwell, M. Feretzaki, V. Leventaki, E. Drakos, H. M. Amin, and G. Z. Rassidakis (2006)
Blood 107, 2544-2547
 |  Abstract »  |  Full Text »  |  PDF »

Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas.

R. Piva, R. Chiarle, A. D. Manazza, R. Taulli, W. Simmons, C. Ambrogio, V. D'Escamard, E. Pellegrino, C. Ponzetto, G. Palestro, et al. (2006)
Blood 107, 689-697
 |  Abstract »  |  Full Text »  |  PDF »

Role of the subcellular localization of ALK tyrosine kinase domain in neuronal differentiation of PC12 cells.

J. Y. Gouzi, C. Moog-Lutz, M. Vigny, and N. Brunet-de Carvalho (2005)
J. Cell Sci. 118, 5811-5823
 |  Abstract »  |  Full Text »  |  PDF »

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.

R. G. W. Verhaak, C. S. Goudswaard, W. van Putten, M. A. Bijl, M. A. Sanders, W. Hugens, A. G. Uitterlinden, C. A. J. Erpelinck, R. Delwel, B. Lowenberg, et al. (2005)
Blood 106, 3747-3754
 |  Abstract »  |  Full Text »  |  PDF »

p130Cas mediates the transforming properties of the anaplastic lymphoma kinase.

C. Ambrogio, C. Voena, A. D. Manazza, R. Piva, L. Riera, L. Barberis, C. Costa, G. Tarone, P. Defilippi, E. Hirsch, et al. (2005)
Blood 106, 3907-3916
 |  Abstract »  |  Full Text »  |  PDF »

Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.

N. Boissel, A. Renneville, V. Biggio, N. Philippe, X. Thomas, J.-M. Cayuela, C. Terre, I. Tigaud, S. Castaigne, E. Raffoux, et al. (2005)
Blood 106, 3618-3620
 |  Abstract »  |  Full Text »  |  PDF »

Nucleophosmin Is Required for DNA Integrity and p19Arf Protein Stability.

E. Colombo, P. Bonetti, E. Lazzerini Denchi, P. Martinelli, R. Zamponi, J.-C. Marine, K. Helin, B. Falini, and P. G. Pelicci (2005)
Mol. Cell. Biol. 25, 8874-8886
 |  Abstract »  |  Full Text »  |  PDF »

Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.

T. Suzuki, H. Kiyoi, K. Ozeki, A. Tomita, S. Yamaji, R. Suzuki, Y. Kodera, S. Miyawaki, N. Asou, K. Kuriyama, et al. (2005)
Blood 106, 2854-2861
 |  Abstract »  |  Full Text »  |  PDF »

Activation of {alpha}-diacylglycerol kinase is critical for the mitogenic properties of anaplastic lymphoma kinase.

R. Bacchiocchi, G. Baldanzi, D. Carbonari, C. Capomagi, E. Colombo, W. J. van Blitterswijk, A. Graziani, and F. Fazioli (2005)
Blood 106, 2175-2182
 |  Abstract »  |  Full Text »  |  PDF »

Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype.

G. Cazzaniga, M. G. Dell'Oro, C. Mecucci, E. Giarin, R. Masetti, V. Rossi, F. Locatelli, M. F. Martelli, G. Basso, A. Pession, et al. (2005)
Blood 106, 1419-1422
 |  Abstract »  |  Full Text »  |  PDF »

Activation and Inhibition of Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase by Monoclonal Antibodies and Absence of Agonist Activity of Pleiotrophin.

C. Moog-Lutz, J. Degoutin, J. Y. Gouzi, Y. Frobert, N. B.-d. Carvalho, J. Bureau, C. Creminon, and M. Vigny (2005)
J. Biol. Chem. 280, 26039-26048
 |  Abstract »  |  Full Text »  |  PDF »

Biological Role of Anaplastic Lymphoma Kinase in Neuroblastoma.

Y. Osajima-Hakomori, I. Miyake, M. Ohira, A. Nakagawara, A. Nakagawa, and R. Sakai (2005)
Am. J. Pathol. 167, 213-222
 |  Abstract »  |  Full Text »  |  PDF »

BEST PRACTICE No 185 Cytological and molecular diagnosis of lymphoma.

G Kocjan (2005)
J. Clin. Pathol. 58, 561-567
 |  Abstract »  |  Full Text »  |  PDF »

Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype.

B. Falini, C. Mecucci, E. Tiacci, M. Alcalay, R. Rosati, L. Pasqualucci, R. La Starza, D. Diverio, E. Colombo, A. Santucci, et al. (2005)
N. Engl. J. Med. 352, 254-266
 |  Abstract »  |  Full Text »  |  PDF »

NPM Mutations in Acute Myelogenous Leukemia.

S. Grisendi and P. P. Pandolfi (2005)
N. Engl. J. Med. 352, 291-292
 |  Full Text »  |  PDF »

Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma.

G. Z. Rassidakis, M. Feretzaki, C. Atwell, I. Grammatikakis, Q. Lin, R. Lai, F.-X. Claret, L. J. Medeiros, and H. M. Amin (2005)
Blood 105, 827-829
 |  Abstract »  |  Full Text »  |  PDF »

Two Decades of Cancer Genetics: From Specificity to Pleiotropic Networks.

S. GRISENDI and P.P. PANDOLFI (2005)
Cold Spring Harb Symp Quant Biol 70, 83-91
 |  Abstract »  |  PDF »

After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies.

M. Wadleigh, D. J. DeAngelo, J. D. Griffin, and R. M. Stone (2005)
Blood 105, 22-30
 |  Abstract »  |  Full Text »  |  PDF »

Peroxisome proliferator-activated receptor {gamma} and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias.

M. Konopleva, E. Elstner, T. J. McQueen, T. Tsao, A. Sudarikov, W. Hu, W. D. Schober, R.-Y. Wang, D. Chism, S. M. Kornblau, et al. (2004)
Mol. Cancer Ther. 3, 1249-1262
 |  Abstract »  |  Full Text »  |  PDF »

A directed screen for genes involved in Drosophila blood cell activation.

C.-J. Zettervall, I. Anderl, M. J. Williams, R. Palmer, E. Kurucz, I. Ando, and D. Hultmark (2004)
PNAS 101, 14192-14197
 |  Abstract »  |  Full Text »  |  PDF »

Expression Profiling of T-Cell Lymphomas Differentiates Peripheral and Lymphoblastic Lymphomas and Defines Survival Related Genes.

B. Martinez-Delgado, B. Melendez, M. Cuadros, J. Alvarez, J. M. Castrillo, A. Ruiz de la Parte, M. Mollejo, C. Bellas, R. Diaz, L. Lombardia, et al. (2004)
Clin. Cancer Res. 10, 4971-4982
 |  Abstract »  |  Full Text »  |  PDF »

Subcellular Localization of Immunohistochemical Signals: Knowledge of the Ultrastructural or Biologic Features of the Antigens Helps Predict the Signal Localization and Proper Interpretation of Immunostains.

W. Cheuk and J. K. C. Chan (2004)
International Journal of Surgical Pathology 12, 185-206
 |  Abstract »  |  PDF »

ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth.

A. Motegi, J. Fujimoto, M. Kotani, H. Sakuraba, and T. Yamamoto (2004)
J. Cell Sci. 117, 3319-3329
 |  Abstract »  |  Full Text »  |  PDF »

Retinoblastoma Protein Is Frequently Absent or Phosphorylated in Anaplastic Large-Cell Lymphoma.

G. Z. Rassidakis, R. Lai, M. Herling, C. Cromwell, A. Schmitt-Graeff, and L. J. Medeiros (2004)
Am. J. Pathol. 164, 2259-2267
 |  Abstract »  |  Full Text »  |  PDF »

Ubiquitination and Proteasomal Degradation of Nucleophosmin-Anaplastic Lymphoma Kinase Induced by 17-Allylamino-Demethoxygeldanamycin: Role of the Co-Chaperone Carboxyl Heat Shock Protein 70-Interacting Protein.

P. Bonvini, H. D. Rosa, N. Vignes, and A. Rosolen (2004)
Cancer Res. 64, 3256-3264
 |  Abstract »  |  Full Text »  |  PDF »

Survivin Expression Predicts Poorer Prognosis in Anaplastic Large-Cell Lymphoma.

E. J. Schlette, L. J. Medeiros, A. Goy, R. Lai, and G. Z. Rassidakis (2004)
J. Clin. Oncol. 22, 1682-1688
 |  Abstract »  |  Full Text »  |  PDF »

Origins, Lineage-Specific Expansions, and Multiple Losses of Tyrosine Kinases in Eukaryotes.

S.-H. Shiu and W.-H. Li (2004)
Mol. Biol. Evol. 21, 828-840
 |  Abstract »  |  Full Text »  |  PDF »

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.

S. Trudel, S. Ely, Y. Farooqi, M. Affer, D. F. Robbiani, M. Chesi, and P. L. Bergsagel (2004)
Blood 103, 3521-3528
 |  Abstract »  |  Full Text »  |  PDF »

Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity.

D. Cussac, C. Greenland, S. Roche, R.-Y. Bai, J. Duyster, S. W. Morris, G. Delsol, M. Allouche, and B. Payrastre (2004)
Blood 103, 1464-1471
 |  Abstract »  |  Full Text »  |  PDF »

Utility of Linearly Amplified RNA for RT-PCR Detection of Chromosomal Translocations: Validation Using the t(2;5)(p23;q35) NPM-ALK Chromosomal Translocation.

J. A. Schumacher, S. D. Jenson, K. S. J. Elenitoba-Johnson, and M. S. Lim (2004)
J. Mol. Diagn. 6, 16-21
 |  Abstract »  |  Full Text »

ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases.

R. D. Gascoyne, L. Lamant, J. I. Martin-Subero, V. S. Lestou, N. L. Harris, H.-K. Muller-Hermelink, J. F. Seymour, L. J. Campbell, D. E. Horsman, I. Auvigne, et al. (2003)
Blood 102, 2568-2573
 |  Abstract »  |  Full Text »  |  PDF »

ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases.

M. Onciu, F. G. Behm, J. R. Downing, S. A. Shurtleff, S. C. Raimondi, Z. Ma, S. W. Morris, W. Kennedy, S. C. Jones, and J. T. Sandlund (2003)
Blood 102, 2642-2644
 |  Abstract »  |  Full Text »  |  PDF »

Complex Genomic Rearrangement of ALK Loci Associated with Integrated Human Epstein-Barr Virus in a Post-Transplant Myogenic Liver Tumor.

M. Debiec-Rychter, R. Croes, R. De Vos, P. Marynen, T. Roskams, A. Hagemeijer, R. Lombaerts, and R. Sciot (2003)
Am. J. Pathol. 163, 913-922
 |  Abstract »  |  Full Text »  |  PDF »

Differential Expression and Clinical Significance of Tyrosine-phosphorylated STAT3 in ALK+ and ALK- Anaplastic Large Cell Lymphoma.

J. D. Khoury, L. J. Medeiros, G. Z. Rassidakis, M. A. Yared, P. Tsioli, V. Leventaki, A. Schmitt-Graeff, M. Herling, H. M. Amin, and R. Lai (2003)
Clin. Cancer Res. 9, 3692-3699
 |  Abstract »  |  Full Text »  |  PDF »

Identification and Characterization of a Nuclear Interacting Partner of Anaplastic Lymphoma Kinase (NIPA).

T. Ouyang, R.-Y. Bai, F. Bassermann, C. von Klitzing, S. Klumpen, C. Miething, S. W. Morris, C. Peschel, and J. Duyster (2003)
J. Biol. Chem. 278, 30028-30036
 |  Abstract »  |  Full Text »  |  PDF »

Prognostic Significance of MUC-1 Expression in Systemic Anaplastic Large Cell Lymphoma.

G. Z. Rassidakis, A. Goy, L. J. Medeiros, Y. Jiang, A. Thomaides, Y. Remache, F. Cabanillas, A. H. Sarris, and F. Gilles (2003)
Clin. Cancer Res. 9, 2213-2220
 |  Abstract »  |  Full Text »  |  PDF »

5'-(RACE) Identification of Rare ALK Fusion Partner in Anaplastic Large Cell Lymphoma.

N. S. Reading, S. D. Jenson, J. K. Smith, M. S. Lim, and K. S. J. Elenitoba-Johnson (2003)
J. Mol. Diagn. 5, 136-140
 |  Full Text »  |  PDF »

Expression of p27Kip1 and c-Jun Activation Binding Protein 1 Are Inversely Correlated in Systemic Anaplastic Large Cell Lymphoma.

G. Z. Rassidakis, F.-X. Claret, R. Lai, Q. Zhang, A. H. Sarris, T. J. McDonnell, and L. J. Medeiros (2003)
Clin. Cancer Res. 9, 1121-1128
 |  Abstract »  |  Full Text »  |  PDF »

NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.

R. Chiarle, J. Z. Gong, I. Guasparri, A. Pesci, J. Cai, J. Liu, W. J. Simmons, G. Dhall, J. Howes, R. Piva, et al. (2003)
Blood 101, 1919-1927
 |  Abstract »  |  Full Text »  |  PDF »

Anaplastic lymphoma kinase (ALK) protein expressing lymphoma after liver transplantation: case report and literature review.

V Costes-Martineau, C Delfour, S Obled, L Lamant, G-P Pageaux, P Baldet, P Blanc, and G Delsol (2002)
J. Clin. Pathol. 55, 868-871
 |  Abstract »  |  Full Text »  |  PDF »

Anti-apoptotic Signaling of Pleiotrophin through Its Receptor, Anaplastic Lymphoma Kinase.

E. T. Bowden, G. E. Stoica, and A. Wellstein (2002)
J. Biol. Chem. 277, 35862-35868
 |  Abstract »  |  Full Text »  |  PDF »

To Advertise   |   Find Products